FOR IMMEDIATE RELEASE

Global Media Contacts:

David Schull or Lena Evans
Russo Partners
+1 212-845-4271
+1 212-845-4262
david.schull@russopartnersllc.com
lena.evans@russopartnersllc.com

David Kujawa
OrbusNeich
+1 954-730-0711 (office)
+1 305-733-7216 (mobile)
dkujawa@orbusneich.com

OrbusNeich’s Genous™ Stent Achieves
Complete Endothelialization at Two Weeks

First Optical Coherence Tomography Case Report of a Patient Requiring Urgent Surgery Two Weeks After Revascularization Published in the Journal of Invasive Cardiology

HONG KONG, April 20, 2012 – OrbusNeich today announced that optical coherence tomography (OCT) results published in the April edition of the Journal of Invasive Cardiology show that the Genous Stent achieves full strut coverage and endothelialization two weeks after percutaneous coronary intervention (PCI). The case report features OCT images of a patient who underwent PCI in advance of a non-deferrable surgery for stomach cancer and who safely discontinued dual antiplatelet therapy (DAPT) at two weeks following revascularization.

The patient, a 78-year old male with chest pain due to an unstable angina, was diagnosed with a tight stenosis in the mid-left anterior descending (LAD) coronary
artery during the preoperative assessment. A plain old balloon angioplasty (POBA) procedure resulted in residual restenosis that required the implantation of a stent. At two-week angiographic follow-up, no in-stent restenosis was observed and OCT showed excellent coverage of the stent struts. Two small aneurysms were observed behind the stent struts that were most likely the result of dissection during the initial POBA procedure. A second OCT performed at four weeks showed that the first aneurysm had completely disappeared and the second had decreased in size.

“By confirming the rapid strut coverage achieved by Genous with OCT, we were able to confidently prescribe the discontinuation of DAPT for this patient at two weeks,” said Jin-Man Cho, M.D., of the Division of Cardiology, Kyung-Hee University at Gangdong, Seoul, Korea. “The Genous Stent may provide an excellent option for patients who require non-deferrable, non-cardiac surgery and for whom early discontinuation of DAPT is required. Previously published studies have also shown that the Genous Stent is safe and associated with low rates of stent thrombosis when accompanied by only two weeks of DAPT.”

**About the Genous Technology**

Genous is OrbusNeich’s patented endothelial progenitor cell (EPC) capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that captures EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

The Genous Stent, which has been commercially available in more than 60 countries since 2005, has been proven as a safe, effective alternative to drug eluting stents and is supported by data from more than 7,000 patients in clinical studies. There is a growing body of evidence from multiple clinical studies that the Genous Stent is effective for patients who are non-responsive to or cannot tolerate long-term dual antiplatelet therapy.
About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world’s first pro-healing stent, the Genous Stent, as well as other stents and balloons marketed under the names of Azule™, R stent, Scoreflex™, Sapphire™, Sapphire II and Sapphire NC. Development stage products include the Combo Dual Therapy Stent™, the only dual therapy stent to both accelerate endothelial coverage and control neo-intimal proliferation through the combination of the Genous pro-healing technology with an abluminal sirolimus drug elution delivered from a biodegradable polymer that achieves full and complete dissolution at 90 days.

OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to interventional cardiologists in more than 60 countries. For more information, visit www.OrbusNeich.com.

Follow OrbusNeich on Twitter at www.twitter.com/OrbusNeich, and learn more about the company and the Genous technology on OrbusNeich’s YouTube Channel: http://www.youtube.com/user/OrbusNeichMedia.

###